CTS (CTS) Q2 2025 Earnings Call July 24, 2025 10:00 AM ET Speaker0Good morning or good afternoon all, and welcome to the CTS Corporation Second Quarter twenty twenty '5 Earnings Call. My name is Adam and I'll be your operator for today. I will now hand the floor to Kieran O'Sullivan, Chairman, President and CEO to begin. So, Kieran, please go ahead when you're ready.Speaker1Good morning and thank you for joining us today for our second quarter twenty twenty five results. We delivered another quarter of doub ...

CTS Corporation 2nd Quarter 2025 Earnings Call July 24, 2025 Cautionary Statement Regarding Forward-Looking Statements Readers are cautioned that the statements contained in this document regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are, or may be deemed to be, "forward-looking statements" as defined by the "safe harbor" provisions in the Private Securities Litigation Reform Act of 1995. Such statements are made in rel ...

Core Insights - Mesoblast Ltd's shares surged nearly 38% following the successful commercial launch of its FDA-approved treatment, Ryoncil®, for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children, with gross revenue of US$13.2 million reported for the first quarter post-launch [1][2] Financial Performance - The company reported a strong financial foundation with US$162 million (A$247 million) in cash at the end of the quarter, positioning it for continued expansion [3] - Mesoblast received US$1.6 million in royalties from the sale of TEMCELL® HS Inj. in Japan through its licensing agreement [3] Regulatory Exclusivity - Ryoncil® received seven years of orphan-drug exclusivity from the FDA for SR-aGvHD in pediatric patients, protecting it from competition in the US market during that period [4] - The company holds biologic exclusivity preventing competitors from referencing Ryoncil®'s biologic license application (BLA) until December 2036, effectively barring biosimilars from entering the market for more than a decade [4] Commercial Launch and Market Coverage - The company has onboarded more than 25 transplant centers, with plans to complete onboarding at 45 priority centers this quarter [6] - Ryoncil® is now insured for more than 250 million US lives through both commercial and government payers, including federal Medicaid, effective from July 1 [6] Future Expansion Plans - Mesoblast is focused on expanding the use of Ryoncil® in adults with SR-aGvHD and has met with the FDA to discuss a pivotal trial for this population [7] - The company is also advancing its second-generation allogeneic MSC therapy, rexlemestrocel-L, for chronic inflammatory diseases, with recent meetings aligning the company and regulators on the pathway to filing for biologics license approval (BLA) [8] Market Reaction - Despite a promising week, investor sentiment has moderated, with shares trading at A$2.32, down 3.73% from Friday highs [9] - The company's long-term prospects remain strong, supported by Ryoncil®'s commercial launch and a robust cash position as it enters the next growth phase [9][10]

Core Viewpoint - Mesoblast Limited has reported strong initial sales of its FDA-approved product Ryoncil, generating gross revenue of US$13.2 million from March 28 to June 30, 2025, following its launch for treating steroid-refractory acute graft-versus-host disease in pediatric patients [1][6][10]. Financial Highlights - Gross revenue from Ryoncil sales reached US$13.2 million (unaudited) from March 28 to June 30, 2025 [6]. - The company reported US$1.6 million in revenue from royalties on sales of TEMCELL HS Inj. in Japan [6]. - Net operating cash spend for the quarter was US$16.6 million [6]. - Cash on hand as of June 30, 2025, was US$162 million (A$247 million) [6]. Operational Highlights - More than 25 transplant centers have been onboarded since the product launch, with plans to complete onboarding across all 45 priority centers that account for approximately 80% of U.S. pediatric transplants [6]. - Ryoncil's coverage is expanding, with over 250 million U.S. lives insured by commercial and government payers, and mandatory Medicaid coverage effective July 1 [6]. - A patient access hub, MyMesoblast™, has been established to assist patients with insurance coverage and access to Ryoncil [6]. Regulatory and Exclusivity Status - Ryoncil received seven years of orphan-drug exclusive approval from the FDA for treating SR-aGvHD in pediatric patients aged 2 months and older [6]. - Mesoblast holds biologic exclusivity preventing another sponsor from referencing Ryoncil's biologic license application until December 2036 [6]. - The company has a strong U.S. intellectual property position on MSC technology, providing commercial barriers to entry against competitors through 2044 [6][12]. Future Developments - Mesoblast held a Type B meeting with the FDA to discuss a pivotal trial for Ryoncil in adults with SR-aGvHD, aiming to extend the product's label [6].

Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapyBASKING RIDGE, N.J. and SUBIACO, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and WARPNINE Incorporated (“WARPNINE”), W ...

Core Insights - The company launched several new products aimed at enhancing database capabilities in the AI era, including KES V9 2025, KEMCC, a cloud database AI version, and KFS Ultra [1] Group 1: KES V9 2025 - KES V9 2025 is designed as a next-generation database benchmark to meet diverse user needs in the AI era, featuring integrated compatibility across multiple syntax systems and data models [2] - It supports compatibility with Oracle, MySQL, SQL Server (99% coverage), and Sybase (95% coverage), along with new support for key-value, document, and vector data models [2] - Performance improvements are achieved through optimizations in computation frameworks, storage organization, and resource scheduling, significantly enhancing overall performance [2] Group 2: KEMCC - KEMCC is introduced as an enterprise-level unified management platform that offers comprehensive database lifecycle management services [3] - The platform integrates the database ecosystem and supports unified management of various database instances across different clouds and environments [3] - It features a visual management interface that simplifies operations and automates management tasks [3] Group 3: Cloud Database AI Version and KFS Ultra - The new cloud database AI version combines the database, hyper-converged platform, high-performance hardware, and AI models to provide a cost-effective private cloud solution [4] - It features the "Chitu Acceleration Engine," achieving a throughput of millions of concurrent connections and sub-millisecond response times, with overall database performance improved by 30% [4] - KFS Ultra is an intelligent data integration platform that supports over a hundred data sources and models, with a daily throughput capacity reaching hundreds of billions [5] - The platform includes an AI assistant for smart operational support, covering installation, performance tuning, and fault diagnosis [5] Group 4: Market Positioning - The company has launched a new brand slogan "Database Replacement with Jincang" to address concerns regarding the complexity and risks of migrating from foreign databases [5] - It offers professional migration solutions that aim to minimize risks, costs, and operational disruptions during the database replacement process [5]

Group 1 - The core viewpoint of the article highlights that Shenzhen Das Intelligent Co., Ltd. has received an A-level rating from Wind ESG, with its comprehensive score rising from 6.18 in 2024 to 7.33, reflecting its significant achievements in the ESG field [2][3] - In the environmental dimension, the company has made notable advancements in green technology innovation and application, including the construction of the first "dual standard, three certifications" super high-rise smart green building in China, which is also the first carbon-neutral building in Shenzhen [2] - As of the end of 2023, the company has provided energy-saving solutions for over 500 buildings nationwide, resulting in a cumulative electricity savings of 1.31 billion kWh and a reduction of approximately 1.305 million tons of carbon dioxide emissions, which strongly supports its environmental score increase [2] Group 2 - The company actively participates in the construction of carbon reduction policy mechanisms, leading the development of the "Shenzhen Efficient Refrigeration Room Carbon Inclusive Methodology" in collaboration with various institutions, aimed at promoting energy-saving and carbon reduction renovations among building owners [2] - The company initiated the "Das Intelligent Building Tenant Carbon Neutrality Invitation," collaborating with five resident enterprises to build a carbon-neutral office ecosystem, exploring sustainable practices and expanding the scope of ESG concepts [3] - In terms of corporate governance, the company adheres to the principles of "long-termism" and "sustainable development," continuously improving its ESG strategic layout and execution system, establishing a scientific, standardized, systematic, and effective ESG governance structure [3]

Core Viewpoint - The rapid growth of the new energy vehicle industry has significantly benefited the lithium battery electrolyte solvent sector, with Haike New Source establishing a leading position in both lithium battery materials and fine chemicals through its "lithium battery materials + consumer chemicals" dual-drive strategy [1][2]. Group 1: Dual-Drive Strategy Effectiveness - The dual-drive strategy has shown remarkable results, driven by the rapid development of the new energy sector and steady growth in consumer chemicals, allowing the company to mitigate risks associated with market fluctuations [2][3]. - Haike New Source is a leading global producer of lithium-ion battery electrolyte solvents, with a comprehensive product range including five types of solvents, establishing high technical barriers and a solid market position [2][3]. - The company's solvent business in consumer chemicals has achieved a leading market share, with significant growth in specialty chemicals, particularly in the bio-based 1,3-butanediol product for cosmetics, which is well-received for its safety and environmental benefits [2][3]. Group 2: Future Resource Allocation and Development - The company plans to increase R&D investment in lithium battery materials, optimize processes to reduce costs, and quickly respond to downstream demand with flexible production lines [3]. - In the consumer chemicals sector, high-end PG sales are expected to grow over 4% in 2025 compared to 2024, supported by market cultivation and new product promotion [3]. - The company aims to optimize resource allocation through coordinated layouts across three major production bases in Shandong, Jiangsu, and Hubei, focusing on small-batch trial production and market promotion to reduce initial operational costs [3]. Group 3: Performance Growth Driven by Production Capacity - The rapid development of the new energy vehicle industry has expanded application scenarios for lithium-ion battery electrolyte solvents and boosted the consumer chemicals sector, providing strong support for the company's performance [4]. - After its listing on the Growth Enterprise Market in 2023, the company has rapidly expanded its business scale, with sales reaching 3.6 billion yuan in 2024, an approximate 8% year-on-year increase, and nearly 1.2 billion yuan in Q1 2025, exceeding a 30% growth rate [4]. - The company attributes its strong performance to cost reductions achieved through raw material optimization, production system improvements, and digital transformation, alongside significant capacity release from its three production bases [4]. Group 4: Competitive Landscape and Overseas Market Expansion - As the domestic lithium-ion battery electrolyte solvent market becomes increasingly saturated, the company is actively expanding into overseas markets, which have significant growth potential [5][6]. - The company has established subsidiaries in Europe and the United States to meet local demand, forming a comprehensive overseas supply chain [5][6]. - In 2023, overseas revenue reached 624 million yuan, accounting for about 20% of total revenue, with a projected sales volume of 33,000 tons of overseas electrolyte solvents in 2024, reflecting a year-on-year growth of 14.31% [6].

□ 通讯员徐欢徐康宁 今年以来，海州区以"开局即决战、起步即冲刺"的姿态，全力加大项目招商与开工力度，推动区域经济 稳健前行。1至5月，高性能粉体材料、连云港"一带一路"临港物联智谷一期等67个新建市重点产业项目 开工，人形机器人关节核心部件、高端EMC产品等12个市重点项目已完工。 新华路、健康路、建南路3条路项目建设现场热火朝天，悦动乡韵运动中心项目跑出加速度，顺丰物流 区域运营中心暨分拨基地项目建设基本完工……夏日的连云港市海州区，处处可见如火如荼的建设场 景，一个个重点项目加速推进，一座座现代化厂房拔地而起。1至5月，海州区117个市重点项目完成投 资85.3亿元，完成年度计划的45.2%，超序时进度3.5个百分点。其中，104个市重点产业项目完成投资 79.9亿元，完成年度计划的46.5%，超序时进度4.8%。 冲刺"双过半"的关键时期，海州区锚定目标任务，以"时不我待"的紧迫感，开启新一轮项目建设攻坚 战。海州区重大项目办相关负责人表示，将坚持"资源要素跟着项目走"，持续强化项目要素保障，实行 专班推进，实施项目全生命周期管理。开辟审批"绿色通道"，提供建设"全程护航"和投产"贴心服务"， 构建全 ...

-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® ...